Copyright
©The Author(s) 2015.
World J Rheumatol. Mar 12, 2015; 5(1): 1-22
Published online Mar 12, 2015. doi: 10.5499/wjr.v5.i1.1
Published online Mar 12, 2015. doi: 10.5499/wjr.v5.i1.1
Table 3 Pharmacological agents implicated in the development of interstitial lung disease in rheumatoid arthritis patients
Pharmacological agent | Relevant information |
DMARDs | |
MTX | Long-term frequency of MTX-induced ILD is 0.43%[35] |
Incidence is 3.78/1000 patients[56] | |
Risk factor for ILD in RA patients (RR = 7.81)[33] | |
LFN | Increases the risk of developing ILD[46] |
Mortality of 19% in patients with LFN-induced ILD[47] | |
AZA | Complication of interstitial pneumonia after treatment with AZA[52] |
TNF-α inhibitors | Mortality is 32% in patients with ILD treated with TNF-α inhibitors[57] |
Etanercept | Incidence of etanercept-induced ILD is 0.6%[73] |
Infliximab | Incidence of infliximab-induced ILD is 0.5%[74] |
- Citation: Olivas-Flores EM, Bonilla-Lara D, Gamez-Nava JI, Rocha-Muñoz AD, Gonzalez-Lopez L. Interstitial lung disease in rheumatoid arthritis: Current concepts in pathogenesis, diagnosis and therapeutics. World J Rheumatol 2015; 5(1): 1-22
- URL: https://www.wjgnet.com/2220-3214/full/v5/i1/1.htm
- DOI: https://dx.doi.org/10.5499/wjr.v5.i1.1